Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a hormone pill shorten the wait after a missed miscarriage?

NCT ID NCT07753655

Disease control Sponsor: Cairo University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This trial tests whether taking letrozole before misoprostol shortens the time to complete uterine evacuation in women with a missed abortion (a pregnancy loss where the embryo stops developing but remains in the uterus). About 74 women will be randomly assigned to receive either letrozole followed by misoprostol or misoprostol alone. The goal is to see if the pretreatment makes the medical evacuation faster and whether it is safe and effective compared to the standard approach.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
letrozole followed by misoprostol
What this could lead to
If effective, this approach could shorten the time needed for medical evacuation, potentially improving the experience and safety for women with missed abortion.
What could go wrong
This is a small trial, and the benefit may be modest or not confirmed. Letrozole may also carry side effects, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 74 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women aged 18 - 45 years. * Diagnosed with missed abortion confirmed by ultrasound (absent fetal heartbeat and/or no embryonic development). * Gestational age ≤ 12 weeks based on last menstrual period * Hemoglobin levels \>10 g/dL. * BMI ranging from 25 to 35 kg/m2. * Hemodynamically stable and no signs of infection. Exclusion Criteria: * Incomplete abortion, inevitable abortion, or threatened miscarriage. * Suspected ectopic pregnancy and molar pregnancy. * History of allergy or contraindication to misoprostol or letrozole. * Coagulopathy or use of anticoagulant medications. * Chronic medical diseases (e.g., uncontrolled diabetes, cardiovascular disease, liver or renal dysfunction). * Prior uterine surgery that contraindicates medical abortion (e.g., classical cesarean section, myomectomy with uterine entry). * Uterine anomalies. * Women unsure of LMP

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Letrozole are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

letrozole toxicity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Letrozole

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.